4/27/2021 7:55:51 AM
Aldeyra Achieves Primary Endpoint And All Secondary Endpoints In Phase 3 Trial Of Reproxalap In Allergic Conjunctivitis
3/11/2021 7:12:40 AM
Aldeyra Therapeutics Net Loss For Full-year 2020 $37.6 Mln Or $1.11 Per Share
1/20/2021 7:08:54 AM
Aldeyra Therapeutics Announces Closing Of Underwritten Public Offering Of 7.87 Mln Shares At $9.50/shr
1/13/2021 4:05:24 PM
Aldeyra Therapeutics Announces Proposed Public Offering Of Common Stock
1/7/2021 7:04:32 AM
Aldeyra Announces Positive Top-Line Results From Run-In Cohort Of Phase 3 TRANQUILITY Trial In Dry Eye Disease
12/22/2020 8:19:41 AM
Aldeyra Therapeutics Announces Confirmation Of SARS-CoV-2 Antiviral Activity Of ADX-1612
12/17/2020 8:08:42 AM
Aldeyra Initiates Phase 2 Trials Of ADX-629 For The Treatment Of COVID-19, Atopic Asthma, And Psoriasis
12/8/2020 8:21:27 AM
Aldeyra Announces Enrollment Of First Patient In Phase 3 TRANQUILITY Trial
7/7/2020 8:16:14 AM
Aldeyra Therapeutics Announces NDA Development Plans For RASP Inhibitor Reproxalap In Dry Eye Disease
6/15/2020 8:04:57 AM
Aldeyra Therapeutics Gets Orphan Medicinal Product Designation From EU For ADX-2191 Retinal Disease Program
5/20/2020 7:11:55 AM
Aldeyra Therapeutics Announces Planned Advancement
of New HSP90 Inhibitor ADX-1612
4/14/2020 8:14:34 AM
Aldeyra Announces Positive Top-Line Phase 1 Clinical Trial Results And Clinical Development Plans For ADX-629